Comparative Study Between Ormeloxifene And Norethisterone In The Management Of Patients Having Dysfunctional Uterine Bleeding : Prospective Randomized Study

Comparative Study Between Ormeloxifene And Norethisterone In The Management Of Dysfunctional Uterine Bleeding - PROSPECTIVE RANDOMIZED STUDY

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020648

Enrollment

Registered

2019-08-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle

Interventions

Intervention1: Tab.Ormeloxifene: 60 mg twice weekly orally for 3months Control Intervention1: Tab.norethisterone: 5 mg Twice a day for 21 days orally for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: Women aged between 19-45 years with diagnosis of AUB

Exclusion criteria

Exclusion criteria: Hypersensitivity to the drug Medical disorders Women desirous of fertility

Design outcomes

Primary

Measure	Time frame
To study effect of ormeloxifene on endometrial thickness in comparision with norethisteroneTimepoint: 12weeks	—

Secondary

Measure	Time frame
Reduction in menstrual blood lossTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDRSHRUTHIA

Shri Sathya Sai Medical College And Research Institute

docsivancgl@gmail.com8610937620

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026